Christina B. Madsen-Duggan

Statistics

Publications

Citations

253

H-Index

Active since

2001

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Christina B. Madsen-Duggan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

2001–2022

Publications

Discovery of <i>N</i>-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

John S. Debenham, Christina B. Madsen-Duggan, Matthew J. Clements et al. · Journal of Medicinal Chemistry · 2016 · 54 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Aryl Amination Using Soluble Weak Base Enabled by a Water-Assisted Mechanism

Sii Hong Lau, Peng Yu, Liye Chen et al. · Journal of the American Chemical Society · 2020 · 35 citations · Full text

Natural Sciences, Chemistry, Medicinal Chemistry +14

Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation. Part 1

John S. Debenham, Christina B. Madsen-Duggan, Richard B. Toupence et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +7

Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists

John S. Debenham, Christina B. Madsen-Duggan, Thomas F. Walsh et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 27 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation

John S. Debenham, Christina B. Madsen-Duggan, Junying Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 17 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

1–5 of 13